INNOVATE PCI investigators. A randomized, double-blind, active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel), a selective and reversible P2Y12 receptor inhibitor vs clopidogrel as a novel antiplatelet therapy in patients undergoing non-urgent percutaneous coronary interventions. European Society of Cardiology 2010 Congress;August 30, 2010;Stockholm, Sweden - Rao, S (Heart J, 2010)
for the